Memantina Ciclum

Memantine, the active ingredient in Memantina Ciclum, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. The drug works by modulating glutamatergic neurotransmission, helping to reduce excitotoxic neuronal damage that contributes to cognitive decline.

GNH USA supplies Memantina Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Memantine is used in the management of neurodegenerative conditions that involve glutamatergic over‑activity.

- Alzheimer's disease (moderate to severe): provides symptomatic improvement in cognition, memory and daily functioning. - Dementia associated with Parkinson's disease: may improve cognitive symptoms and functional abilities. - Lewy body dementia: can help stabilize cognition and reduce fluctuations.

Memantine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity, often resolving without intervention. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Fatigue: feeling unusually tired or lacking energy.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Seizures: occurrence of convulsive episodes, particularly in patients with a seizure history. - Cardiac arrhythmias: irregular heart rhythms that may need cardiology evaluation. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.

Before prescribing Memantina Ciclum, clinicians should consider several safety aspects. - Renal impairment: dose may need adjustment or close monitoring of renal function. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Concomitant NMDA antagonists: avoid combined use to reduce risk of additive toxicity. - Pregnancy: safety unknown; avoid unless potential benefit justifies the risk. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantine can interact with other medications, requiring awareness of the interaction level.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can lead to excessive central nervous system depression. - Other NMDA antagonists: concurrent use may amplify adverse neurological effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish the cognitive benefits of memantine. - Diuretics: can affect renal clearance, necessitating dose review. - CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation.